|
|
|
|
| LEADER |
01565 am a22001933u 4500 |
| 001 |
130354 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Mahoney, Andrew R.
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemical Engineering
|e contributor
|
| 700 |
1 |
0 |
|a Safaee, Mohammad Moein
|e author
|
| 700 |
1 |
0 |
|a Wuest, William M.
|e author
|
| 700 |
1 |
0 |
|a Furst, Ariel L.
|e author
|
| 245 |
0 |
0 |
|a The silent pandemic: Emergent antibiotic resistances following the global response to SARS-CoV-2
|
| 260 |
|
|
|b Elsevier BV,
|c 2021-04-02T19:27:59Z.
|
| 856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/130354
|
| 520 |
|
|
|a The ongoing SARS-CoV-2 pandemic has highlighted the importance of the rapid development of vaccines and antivirals. However, the potential for the emergence of antibiotic resistances due to the increased use of antibacterial cleaning products and therapeutics presents an additional, underreported threat. Most antibacterial cleaners contain simple quaternary ammonium compounds (QACs), however these compounds are steadily becoming less effective as antibacterial agents. QACs are extensively used in SARS-CoV-2 related sanitization in clinical and household settings. Similarly, due to the danger of secondary infections, antibiotic therapeutics are increasingly used as a component of COVID-19 treatment regimens, even in the absence of a bacterial infection diagnosis. The increased use of antibacterial agents as cleaners and therapeutics is anticipated to lead to novel resistances in the coming years.
|
| 546 |
|
|
|a en
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t iScience
|
